SR ONE CAPITAL MANAGEMENT, LLC reported conversion involving 198,019 derivative units of ADARx Pharmaceuticals, Inc. at $0.00 for $0 on Sep 28, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
10% owner
10%
Filed Sep 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
198,019Series B-1 Preferred Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Indirect · See Note 4
Trade date
Sep 28, 2026Conversion
Filed
Sep 29, 2026, 9:45 PM ET2-day reporting delay
Accession
0001193125-26-408064Code C · Transaction 231497
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 28, 2026Conversion1,304,883$0.00$0Trade 231493
Sep 28, 2026Buy592,593$17.00$10,074,081Trade 231486
Sep 28, 2026Buy414,814$17.00$7,051,838Trade 231488
Sep 28, 2026Buy592,593$17.00$10,074,081Trade 231491
Sep 28, 2026Conversion600,962$0.00$0Trade 231494
Sep 28, 2026Conversion1,802,885$0.00$0Trade 231495
Sep 28, 2026Conversion3,907,547$0.00$0Trade 231492
Sep 28, 2026Conversion1,953,773$0.00$0Trade 231496
Sep 28, 2026Conversion3,334,938——Trade 231483
Sep 28, 2026Conversion1,113,666——Trade 231484
Sep 28, 2026Conversion512,897——Trade 231485
Sep 28, 2026Conversion1,538,691——Trade 231487
Sep 28, 2026Conversion1,667,468——Trade 231489
Sep 28, 2026Conversion169,001——Trade 231490
15 transaction rows in this filing. Joint filers share the same rows.

ADRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −13%30d −10%90d180d1y

Footnotes in full

F1: Each share of Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 reverse stock split basis into shares of Common Stock upon the closing of the Issuer's initial public offering on September 28, 2026, without payment of further consideration. The Preferred Stock has no expiration date. F2: The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. F3: The securities are directly held by SR One Capital Opportunities Fund I, LP ("SR One Opportunities Fund I"). SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I") is the sole general partner of SR One Opportunities Fund I, and SR One Capital Management is the sole general partner of SR One Opportunities Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Opportunities Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. F4: The securities are directly held by SR One Co-Invest III, LLC ("SR One Co-Invest"). SR One Co-Invest III Manager LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. F5: The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.